Psychopharmacology

Lighthouse Pharmaceuticals Announces Presentation at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting

Retrieved on: 
Wednesday, May 24, 2023
Therapy, Porphyromonas gingivalis, Psychopharmacology, SAD, Research, Bangladesh Technical Education Board, ASCP, SPRING, Alzheimer's disease, Pharmacist, SAN, Treatment, Annual general meeting, MAD, Food, Pharmaceutical industry, MD

SAN FRANCISCO, May 24, 2023 /PRNewswire/ -- Lighthouse Pharmaceuticals, a clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer's and other degenerative diseases, announced the upcoming presentation of new data and strategic plans in a Plenary Presentation during the Pharmaceutical Pipeline session. The accepted abstract, entitled "Phase 2 Study Design and New Data from the Phase 1 SAD/MAD Trial of LHP588, a Second-Generation Gingipain Inhibitor for the Treatment of P. Gingivalis-Associated Dementia," will share new data related to the single ascending dose (SAD) and multiple ascending dose (MAD) trials of LHP588. Additionally, the design and clinical efficacy data supporting the planned Phase 2b SPRING (Stopping PRogression of Porphyromonas gINGivalis associated Alzheimer's disease) Trial will be shared.

Key Points: 
  • SAN FRANCISCO, May 24, 2023 /PRNewswire/ -- Lighthouse Pharmaceuticals, a clinical-stage pharmaceutical company developing therapeutics to alter the course of Alzheimer's and other degenerative diseases, announced the upcoming presentation of new data and strategic plans in a Plenary Presentation during the Pharmaceutical Pipeline session.
  • Additionally, the design and clinical efficacy data supporting the planned Phase 2b SPRING (Stopping PRogression of Porphyromonas gINGivalis associated Alzheimer's disease) Trial will be shared.
  • "The SPRING trial will include precision enrollment criteria for both Alzheimer's disease and P. gingivalis infection informed by the previously completed Phase 2/3 study of the first-generation molecule."
  • The ASCP annual meeting is being held May 30th – June 2nd, and the presentation will be on Tuesday May 30 in the Pharmaceuticals Pipeline session at 3:10 pm and a poster will also be presented on Wednesday May 31 at 11:15 am.

Click Therapeutics and Boehringer Ingelheim Initiate Pivotal Clinical Trial of Prescription Digital Therapeutics for the Treatment of Negative Symptoms in Schizophrenia

Retrieved on: 
Thursday, May 4, 2023
Software, Biotechnology, Pharmaceutical, General Health, Health, FDA, Technology, Clinical Trials, Consensus, Consensus decision-making, Hallucination, Partnership, Therapy, Motivation, Disability, Perception, Clinical trial, Psychopharmacology, Mental health, DSM-IV codes, NIMH, Doctor of Philosophy, CNS, Boehringer Ingelheim, MD, Patient, Risk, Diagnosis, Digital, National Institute of Mental Health, FAAN, Behavior, Disease, Pharmaceutical industry, Nursing, Schizophrenia

Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced the initiation of the CONVOKE Study , a registrational clinical trial to investigate the use of prescription digital therapeutics as an adjunct treatment to standard of care antipsychotic therapy to treat the negative symptoms of schizophrenia in patients 18 years and older.

Key Points: 
  • Click Therapeutics, Inc. (“Click”), a leader in Digital Therapeutics™ as prescription medical treatments, today announced the initiation of the CONVOKE Study , a registrational clinical trial to investigate the use of prescription digital therapeutics as an adjunct treatment to standard of care antipsychotic therapy to treat the negative symptoms of schizophrenia in patients 18 years and older.
  • The study intervention period will be 16 weeks and efficacy will be assessed by the Clinical Assessment Interview for Negative Symptoms, Motivation and Pleasure scale (CAINS-MAP).
  • The CAINS-MAP measures experiential negative symptoms, the clinical target of interest in the evaluation of efficacy in this study.
  • “Our partnership with Click Therapeutics, who share a like-minded goal through our approach to prescription digital therapeutics, has the potential to address significant unmet needs in schizophrenia.

 Cybin to Participate at the 26th Annual Milken Institute Global Conference

Retrieved on: 
Friday, April 28, 2023
Science, Biotechnology, Research, Pharmaceutical, Health, FDA, Mental Health, Clinical Trials, Psychopharmacology, Systematic review, Inc., Depression, Journal of Affective Disorders, Event, Anxiety, Quality of life, PT, Bangladesh Technical Education Board, Mental, Milken Institute, DSM-IV codes, Patient, Journal of Psychopharmacology, Mental health, Safety, The Beverly Hilton, NYSE, Conference, World Health Organization, NEO, Nursing, Pharmaceutical industry

The Milken Institute is a nonprofit, nonpartisan think tank dedicated to connecting resources and innovation so the best ideas can succeed.

Key Points: 
  • The Milken Institute is a nonprofit, nonpartisan think tank dedicated to connecting resources and innovation so the best ideas can succeed.
  • To access the live panel discussion, please click here .
  • The archived webcast will also be available on the Company’s investor relations website on the Events & Presentations page.
  • For more information on the Milken Institute and the upcoming conference visit www.milkeninstitute.org .

Reviva Pharmaceuticals to Host Key Opinion Leader Event on Brilaroxazine (RP5063) in Phase 3 Clinical Trials for Schizophrenia

Retrieved on: 
Tuesday, April 25, 2023
Molecule, PD, Pharmacogenomics, Drug, Patient, Environment, Neurology, Clinical, BCPP, University, CSO, Allodynia, Parexel, DSM-IV codes, Capsaicin, Magnetic resonance, MRS, RP5063, UV, NGF, FIH, CSF, Serotonin, ChromeOS, Safety, Public key certificate, FCCP, Research, Neurodegenerative disease, KOL, Central nervous system, Drug development, Doctor of Pharmacy, UT, PET, CNS, Bipolar disorder, AD, APEX, Pharmacology, Pharmaceutical industry, Schizophrenia, Psychopharmacology, Depression, Psychiatry, Pharmacy

He will look at brilaroxazine, a next-generation serotonin-dopamine modulator, and its potential as a treatment solution for schizophrenia.

Key Points: 
  • He will look at brilaroxazine, a next-generation serotonin-dopamine modulator, and its potential as a treatment solution for schizophrenia.
  • The Reviva leadership team will provide an overview of the efficacy and safety data generated in the clinical trials completed to date and an update on ongoing RECOVER Phase 3 trial evaluating brilaroxazine in patients with acute schizophrenia.
  • Brilaroxazine is a new chemical entity with broad therapeutic potential in neuropsychiatric and inflammatory conditions arising from underlying dysfunction in serotonin and dopamine signaling.
  • Dr. Ereshefsky’s unique perspective as a clinical scientist (clinical psychiatric pharmacist and psychopharmacologist) helps to guide drug development from preclinical to late Phase.

Reunion Neuroscience Provides Business Update and Reports Fiscal Third Quarter 2023 Financial Results

Retrieved on: 
Tuesday, February 14, 2023
Bank statement, GSK, Woman, Mother, TSX, Data analysis, Investment, PPD, IAS, ID, Safety, Patient, Depression, Webcast, International Financial Reporting Standards, Reunion, Congress, Takeda, Psilocybin, Psychopharmacology, International, FDA, Consciousness, Research, Wellness, Spinout, AstraZeneca, Drug discovery, Toronto Stock Exchange, Selective serotonin reuptake inhibitor, Management, Pharmaceutical industry, Audit, Cryptocurrency, Pfizer, Merck

TORONTO, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a clinical-stage biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, today provided a business update and reported fiscal results for the third quarter ended December 31, 2022.

Key Points: 
  • In January 2023, Reunion completed its Phase 1 interim data analysis, which showed that RE104 was safe and well tolerated, with no serious or severe adverse events.
  • Exploring further doses with the two additional planned cohorts will provide Reunion with valuable data to inform selection of a recommended Phase 2 dose.
  • Reunion will conduct a conference call and webcast to discuss its results on February 14, 2023, at 8:30 a.m.
  • A live webcast of the conference call can be accessed via the “Events and Presentations” section of the Reunion investor relations website here .

HMP Global names Dr. Craig Chepke as Scientific Advisor for Psych Congress Educational Programs

Retrieved on: 
Thursday, January 26, 2023
History, American Psychiatric Association, MPH, DSM-IV codes, Education, Congress, Health, Distinguished Fellow of the British Computer Society, Faculty, Psychiatry, Atrium Health, Texas Tech University Health Sciences Center School of Medicine, Associate, Patient, Psychopharmacology, Attention deficit hyperactivity disorder, Research, Mental health, Texas Tech University School of Law, Pharmaceutical industry, Nursing, MD

MALVERN, Pa., Jan. 26, 2023 /PRNewswire-PRWeb/ -- HMP Global, the leading omnichannel healthcare company, today announced that Psych Congress Steering Committee member Dr. Craig Chepke has been named Scientific Advisor for the entire Psych Congress portfolio, including Psych Congress, the nation's largest independent mental health educational conference on practical psychopharmacology, Psych Congress Elevate, Psych Congress Regionals, and the newly announced Psych Congress NP Institute In-Person event.

Key Points: 
  • MALVERN, Pa., Jan. 26, 2023 /PRNewswire-PRWeb/ -- HMP Global, the leading omnichannel healthcare company, today announced that Psych Congress Steering Committee member Dr. Craig Chepke has been named Scientific Advisor for the entire Psych Congress portfolio, including Psych Congress , the nation's largest independent mental health educational conference on practical psychopharmacology, Psych Congress Elevate , Psych Congress Regionals , and the newly announced Psych Congress NP Institute In-Person event.
  • As Scientific Advisor, Dr. Chepke will work closely with the steering committees and faculty of Psych Congress events and programs to develop high-quality practical and advanced evidence-based educational content relevant to all mental health team members.
  • "I've heard Dr. Chepke described as a rising star, but I disagree," said Rakesh Jain, MD, MPH, Psych Congress Co-Chair and Clinical Professor of Psychiatry at Texas Tech University School of Medicine.
  • For more information or to register for this and other upcoming Psych Congress events, visit psychcongress.com .

Reunion Neuroscience Appoints Robert Alexander as Chief Medical Officer

Retrieved on: 
Wednesday, January 18, 2023
American Board of Psychiatry and Neurology, Protalix BioTherapeutics, Merck, Pharmacology, Mental health, CNS, American Board of Commissioners for Foreign Missions, Reunion, TSX, Head, Merck & Co., AstraZeneca, Patient, Clinical neuroscience, Neurology, University, Data analysis, Takeda Pharmaceutical Company, Pfizer, GSK, Psychiatry, Psychopharmacology, Pharmaceutical industry, GlaxoSmithKline, Takeda

TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed Robert Alexander, M.D.

Key Points: 
  • TORONTO, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc. (NASDAQ: REUN, TSX: REUN) (“Reunion” or “the Company”), a biopharmaceutical company committed to developing innovative and patented therapeutic solutions for underserved mental health conditions, announced today that it has appointed Robert Alexander, M.D.
  • as the Company’s Chief Medical Officer, effective immediately.
  • Prior to Takeda, Dr. Alexander served as Chief Medical Officer, BioTherapeutics, at Pfizer, directing clinical pharmacology and statistics groups while simultaneously holding the position of Vice President and Head of the Clinical Neuroscience and Pain Research Unit at the company.
  • Second, the Company’s strong intellectual property position gives Reunion a significant competitive advantage over others in the space,” added Dr. Alexander.

Reunion Neuroscience Inc. Completes Interim Data Analysis for Phase 1 Clinical Trial with Novel Serotonergic Psychedelic RE104

Retrieved on: 
Monday, January 9, 2023
Psilocybin, IND, Psychopharmacology, Data, ACS, Emmanuel Berl, Depression, Mental health, Anxiety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Pharmacokinetics, Safety, Reunion, TSX, FDA, SRC, The New England Journal of Medicine, Food, Patient, Drug discovery, Data analysis, Pharmaceutical industry

RE104 is a proprietary, novel serotonergic psychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions.

Key Points: 
  • RE104 is a proprietary, novel serotonergic psychedelic compound that Reunion is developing as a potential fast-acting and durable treatment for patients suffering from postpartum depression and other mental health conditions.
  • In this first-in-human, Phase 1 study, RE104 was shown to be safe and well tolerated, with no serious or severe adverse events.
  • The interim analysis included 32 healthy volunteers across four ascending dose cohorts, with two of the eight subjects in each cohort receiving placebo.
  • While completing the preplanned interim analysis, and per the recommendation of the Safety Review Committee (SRC), Reunion has continued with dose escalation and initiated a fifth cohort.

Majority of Stockholders Support Pasithea Directors at Special Meeting

Retrieved on: 
Wednesday, December 14, 2022
Shareholder, Psychopharmacology, Multiple sclerosis, Psychiatry, Noonan syndrome, CNS, Amyotrophy, Security (finance), ALS, Biotechnology, Amyotrophic lateral sclerosis, Central nervous system, Independent, Special, MIAMI, Neuroscience, KTTA, Research, Therapy, Pharmaceutical industry

MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced the final results of the Special Meeting of Stockholders (“Special Meeting”) held on December 9, 2022.

Key Points: 
  • MIAMI BEACH, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders, today announced the final results of the Special Meeting of Stockholders (“Special Meeting”) held on December 9, 2022.
  • According to the certified voting results provided by the Independent Inspector of Elections, a significant majority of Pasithea stockholders rejected all of the proposals asserted by a dissident group of stockholders.
  • Of the votes cast at the Special Meeting, approximately 67% rejected the proposals to remove the Company’s directors, representing approximately 12.7 million shares or approximately 44% of the total outstanding shares.
  • Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders.

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

Retrieved on: 
Monday, December 12, 2022
Shareholder, Concord, Psychopharmacology, Multiple sclerosis, Psychiatry, LP, Noonan syndrome, CNS, Amyotrophy, Security (finance), ALS, Agreement, Biotechnology, Amyotrophic lateral sclerosis, Central nervous system, MIAMI, Neuroscience, Prejudice, KTTA, Research, Cooperation, Therapy, Patient, Pharmaceutical industry, Pasithea (Charites)

Pursuant to the Agreement, the Camac Group has agreed to a three-year standstill provision and the parties have agreed to dismiss with prejudice the pending Delaware litigation against the Company and the Board filed by the Camac Group.

Key Points: 
  • Pursuant to the Agreement, the Camac Group has agreed to a three-year standstill provision and the parties have agreed to dismiss with prejudice the pending Delaware litigation against the Company and the Board filed by the Camac Group.
  • Pasithea will also reimburse certain fees and expenses of the Camac Group.
  • We are excited about Pasithea’s potential to advance our therapies and achieve value-creating milestones.”
    Eric Shahinian of the Camac Group further commented, “We are pleased to have reached this settlement with Pasithea.
  • Pasithea Therapeutics is a biotechnology company primarily focused on the discovery, research and development of innovative treatments for central nervous system (CNS) disorders.